Yellow Fever Clinical Trial
Official title:
Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children
In a previous study by the researchers' group, the researchers' investigate the duration of yellow fever post-vaccination immunity in vaccinated children between 9 and 23 months of age. However, in this study, samples of children in the pre-vaccine period, also known as unvaccinated children samples (NV) have not been investigated. It is believed that to seek evidence about the immune status in the medium and long term after vaccination against yellow fever is necessary to investigate paired samples of children not vaccinated (NV), with re-evaluation 30-45 days after primary vaccination. The proposed study is to consolidate aspects of humoral (neutralizing antibodies) and cellular (phenotypic and functional parameters of T cells and memory B) by means of complementary longitudinal investigation children, 9-23 months old, unvaccinated (NV) and 30-45 days after primary vaccination.
A sample of 60 children aged 9 to 23 months paired in the pre-vaccine period (NV) and 30-45
post-primary vaccination days will be selected at health facilities in the metropolitan
region of Belo Horizonte.
Children whose mothers consent to participate in research, have collected blood and elements
of past medical history recorded. Analyses of humoral and cellular biomarkers will be used in
a comparative study with other post-vaccination periods previously analyzed in children
during the first phase in study funded by the Ministry of Health.
specific objectives:
1. Estimate and compare the proportion of positivity and the geometric mean plasma titers
of neutralizing antibodies against yellow fever;
2. Assess lymphocyte frequency T and B memory induced in vitro by the vaccine antigen 17DD
substrains, and...
3. Quantify the lymphocytes T CD8 + producers of intracytoplasmic cytokines induced in
vitro by the vaccine antigen 17DD substrains in unvaccinated children and primed aged
between 9 and 23 months, categorized according to the vaccination time 30-45 days.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01436396 -
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
|
Phase 3 | |
| Recruiting |
NCT05568953 -
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
|
Phase 2 | |
| Recruiting |
NCT05447377 -
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants
|
Phase 3 | |
| Active, not recruiting |
NCT05011123 -
Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia
|
Phase 2 | |
| Completed |
NCT04267809 -
Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection
|
Phase 2 | |
| Completed |
NCT01943305 -
The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans
|
Phase 2 | |
| Completed |
NCT02991495 -
Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)
|
Phase 4 | |
| Not yet recruiting |
NCT03725618 -
Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old
|
Phase 4 | |
| Completed |
NCT01466387 -
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
|
Phase 3 | |
| Completed |
NCT04059471 -
Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine
|
Phase 4 | |
| Completed |
NCT02572518 -
Immunity After Two Doses of Yellow Fever Vaccine
|
N/A | |
| Recruiting |
NCT00694655 -
Human Immune Responses to Yellow Fever Vaccination
|
Phase 4 | |
| Not yet recruiting |
NCT05332197 -
Booster Vaccine for Yellow Fever
|
Phase 3 | |
| Recruiting |
NCT05421611 -
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
|
Phase 3 | |
| Completed |
NCT03116802 -
Yellow Fever Vaccine on Statin/ Non Statin Subjects
|
Phase 2 | |
| Completed |
NCT02743455 -
A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01426243 -
The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.
|
Phase 3 | |
| Completed |
NCT00982137 -
Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)
|
Phase 2 | |
| Active, not recruiting |
NCT04269265 -
The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination
|
Phase 1/Phase 2 | |
| Completed |
NCT03870061 -
Evaluation of an Infant Immunization Encouragement Program in Nigeria
|
N/A |